Back to News
Market Impact: 0.35
Kyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026
Source: GlobeNewswire
Healthcare & Biotech
Full one-year results from the KYSA-8 registrational trial in stiff person syndrome are to be reported, with the source describing sustained clinical benefit and a well-tolerated safety profile. It reports no high-grade CRS or ICANS and no cases of IEC-HS; the article provides no efficacy figures or event rates.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.40
More News
- Profound Medical stock surges 20% on raised Q3 revenue outlook
- Medical device maker Centinel Spine discloses revenue rise in US IPO filing
- Halozyme stock rises after winning injunction against Merck
- BTIG cuts ArriVent BioPharma stock price target on trial results
- MustGrow Biologics at 20th iif: sales grow as Bayer backs pipeline
- AVBP SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving ArriVent BioPharma
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AI Tools for CFA Charterholders: An Evidence Standard
- Weekly Update: Unstructured Data Search, Ask AI, and Advanced Futures Data